[{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"21be25ed-db5c-4f88-af53-6dabef3b154a","acronym":"SUMIT-ELA","url":"https://clinicaltrials.gov/study/NCT05963997","created_at":"2023-07-27T17:09:07.832Z","updated_at":"2025-02-25T13:41:37.681Z","phase":"Phase 1/2","brief_title":"A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","source_id_and_acronym":"NCT05963997 - SUMIT-ELA","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 10/09/2023","start_date":" 10/09/2023","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-02-21"},{"id":"3f832c54-ae2b-45dd-b72a-df4624a79314","acronym":"SUMIT-BC","url":"https://clinicaltrials.gov/study/NCT05963984","created_at":"2023-07-27T17:09:07.566Z","updated_at":"2025-02-25T13:41:37.189Z","phase":"Phase 2","brief_title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","source_id_and_acronym":"NCT05963984 - SUMIT-BC","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"eef00741-67ea-4f6a-a30f-9aebbb089fa9","acronym":"NeoVAB","url":"https://clinicaltrials.gov/study/NCT03876951","created_at":"2021-01-18T19:06:42.497Z","updated_at":"2025-02-25T14:07:21.577Z","phase":"","brief_title":"Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)","source_id_and_acronym":"NCT03876951 - NeoVAB","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • ER negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2025-02-17"},{"id":"10294ca2-7f84-44ce-af11-76cdd03b1746","acronym":"SERENA-2","url":"https://clinicaltrials.gov/study/NCT04214288","created_at":"2021-01-18T20:31:16.451Z","updated_at":"2025-02-25T14:40:27.343Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04214288 - SERENA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 04/22/2020","start_date":" 04/22/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-14"},{"id":"dc4d04a6-0615-4ba1-8e7e-f73bd8437cb0","acronym":"CAAA603B12101","url":"https://clinicaltrials.gov/study/NCT05870579","created_at":"2023-05-23T16:06:09.074Z","updated_at":"2025-02-25T14:42:04.037Z","phase":"Phase 1","brief_title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","source_id_and_acronym":"NCT05870579 - CAAA603B12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2023","start_date":" 11/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 01/26/2032","study_completion_date":" 01/26/2032","last_update_posted":"2025-02-14"},{"id":"e8ce3ccf-c1c8-4ee0-b8b5-f9d8061d44e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00667121","created_at":"2021-01-18T02:29:16.873Z","updated_at":"2025-02-25T14:39:15.807Z","phase":"","brief_title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","source_id_and_acronym":"NCT00667121","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 03/16/2011","start_date":" 03/16/2011","primary_txt":" Primary completion: 05/12/2014","primary_completion_date":" 05/12/2014","study_txt":" Completion: 05/27/2014","study_completion_date":" 05/27/2014","last_update_posted":"2025-02-14"},{"id":"d4382874-e25d-4b5e-9edf-2da01d094584","acronym":"SOLAR-1","url":"https://clinicaltrials.gov/study/NCT02437318","created_at":"2021-01-17T17:15:58.321Z","updated_at":"2025-02-25T15:10:15.914Z","phase":"Phase 3","brief_title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","source_id_and_acronym":"NCT02437318 - SOLAR-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • HER-2 negative + ER positive","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 572","initiation":"Initiation: 07/23/2015","start_date":" 07/23/2015","primary_txt":" Primary completion: 06/12/2018","primary_completion_date":" 06/12/2018","study_txt":" Completion: 06/09/2023","study_completion_date":" 06/09/2023","last_update_posted":"2025-02-13"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"99f591b9-7e23-4ea7-a5a0-fe1e2287e1db","acronym":"KEYNOTE-F21","url":"https://clinicaltrials.gov/study/NCT04225117","created_at":"2021-01-18T20:34:06.535Z","updated_at":"2025-02-25T15:18:27.870Z","phase":"Phase 2","brief_title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","source_id_and_acronym":"NCT04225117 - KEYNOTE-F21","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-12"},{"id":"155f3329-d4dc-4e2c-bac9-4feb6555c97c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659797","created_at":"2022-12-21T14:58:43.479Z","updated_at":"2025-02-25T15:20:11.117Z","phase":"Phase 1","brief_title":"FES BPET-DBT in Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT05659797","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-11"},{"id":"a22b0db3-f6b3-489e-b362-7e9a7131a6f7","acronym":"ELECTRA","url":"https://clinicaltrials.gov/study/NCT05386108","created_at":"2022-05-23T15:53:51.405Z","updated_at":"2025-02-25T15:27:22.960Z","phase":"Phase 1/2","brief_title":"Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer","source_id_and_acronym":"NCT05386108 - ELECTRA","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"343860fb-1c41-454c-a2e5-97b25f553d79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02954874","created_at":"2021-01-18T14:30:57.547Z","updated_at":"2025-02-25T16:44:03.478Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","source_id_and_acronym":"NCT02954874","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1155","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-06"},{"id":"8147029b-82ff-40c1-8ad2-7d7475cad70d","acronym":"RE-IORT01","url":"https://clinicaltrials.gov/study/NCT02386371","created_at":"2021-01-18T11:22:26.484Z","updated_at":"2025-02-25T16:36:31.813Z","phase":"","brief_title":"Intraoperative Radiotherapy After Local Recurrence in Breast Cancer","source_id_and_acronym":"NCT02386371 - RE-IORT01","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 06/12/2020","primary_completion_date":" 06/12/2020","study_txt":" Completion: 09/18/2023","study_completion_date":" 09/18/2023","last_update_posted":"2025-02-06"},{"id":"c4e11efc-9d5b-4b66-8405-a37c7fb6999f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865992","created_at":"2021-01-18T19:04:02.353Z","updated_at":"2025-02-25T16:44:35.724Z","phase":"","brief_title":"Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease","source_id_and_acronym":"NCT03865992","lead_sponsor":"City of Hope Medical Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2025-02-06"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2025-02-25T12:28:43.790Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 922","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-04"},{"id":"593bd291-2adc-49c4-bd0f-7562aaaad9cd","acronym":"RIBOLARIS","url":"https://clinicaltrials.gov/study/NCT05296746","created_at":"2022-03-26T00:55:02.980Z","updated_at":"2025-02-25T15:54:25.627Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","source_id_and_acronym":"NCT05296746 - RIBOLARIS","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2025-02-04"}]